These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37107125)

  • 1. Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis.
    Gatti M; Fornaro G; Pasquini Z; Zanoni A; Bartoletti M; Viale P; Pea F
    Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Inflammatory Burden on Voriconazole Exposure in Oncohematological Pediatric Patients Receiving Antifungal Prophylaxis after Allogeneic HCT.
    Gatti M; Campoli C; Muratore E; Belotti T; Masetti R; Lanari M; Viale P; Pea F
    Microorganisms; 2024 Jul; 12(7):. PubMed ID: 39065156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective analysis of patient-specific factors on voriconazole clearance.
    Dote S; Sawai M; Nozaki A; Naruhashi K; Kobayashi Y; Nakanishi H
    J Pharm Health Care Sci; 2016; 2():10. PubMed ID: 27096102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
    Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
    Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers.
    Cojutti P; Candoni A; Forghieri F; Isola M; Zannier ME; Bigliardi S; Luppi M; Fanin R; Pea F
    Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):474-9. PubMed ID: 26572687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study.
    Kim SH; Hong JY; Bae S; Lee H; Wi YM; Ko JH; Kim B; Joo EJ; Seok H; Shi HJ; Yoo JR; Hyun M; Kim HA; Jang S; Mun SJ; Kim J; Kim MC; Jung DS; Kim SH; Peck KR
    J Korean Med Sci; 2022 May; 37(18):e134. PubMed ID: 35535369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional Impact of COVID-19-Associated Pulmonary Aspergillosis (CAPA) during the First Wave.
    Bentvelsen RG; Arkel ALEV; Rijpstra TA; Kant MKM; Brugge SVS; Loth DW; Van Wijngaarden P; Mée AWFD; Yick DCY; Diederen BMW; Wever PC; Leenders ACAP; Van Dommelen L; Groot KH; Van den Bijllaardt W; Verweij PE
    J Fungi (Basel); 2022 Jan; 8(2):. PubMed ID: 35205851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated.
    Gautier-Veyret E; Thiebaut-Bertrand A; Roustit M; Bolcato L; Depeisses J; Schacherer M; Schummer G; Fonrose X; Stanke-Labesque F
    Br J Clin Pharmacol; 2021 Jun; 87(6):2534-2541. PubMed ID: 33217017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation is associated with voriconazole trough concentrations.
    van Wanrooy MJ; Span LF; Rodgers MG; van den Heuvel ER; Uges DR; van der Werf TS; Kosterink JG; Alffenaar JW
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7098-101. PubMed ID: 25223994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
    Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
    Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of extracorporeal membrane oxygenation on voriconazole plasma concentrations: A retrospective study.
    Ye Q; Yu X; Chen W; Li M; Gu S; Huang L; Zhan Q; Wang C
    Front Pharmacol; 2022; 13():972585. PubMed ID: 36059951
    [No Abstract]   [Full Text] [Related]  

  • 12. Assessing the safety profile of voriconazole use in suspected COVID-19-associated pulmonary aspergillosis-a two-centre observational study.
    Costa-Pinto R; Klink S; Rotherham H; Perera P; Finlay L; Urbancic K; Vaz K; Trubiano J; Bellomo R
    Med Mycol; 2023 Jun; 61(6):. PubMed ID: 37286877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: dose-dependent interaction between dexamethasone and voriconazole in severely ill patients with non-Hodgkin's lymphoma being treated for invasive pulmonary aspergillosis.
    Huang J; Chen Y; Zhong M; Tan R
    Front Pharmacol; 2024; 15():1403966. PubMed ID: 38994198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: A nationwide multi-centre retrospective study.
    Wang T; Miao L; Shao H; Wei X; Yan M; Zuo X; Zhang J; Hai X; Fan G; Wang W; Hu L; Zhou J; Zhao Y; Xie Y; Wang J; Guo S; Jin L; Li H; Liu H; Wang Q; Chen J; Li S; Dong Y
    Int J Antimicrob Agents; 2022; 60(5-6):106692. PubMed ID: 36372345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy.
    Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study.
    Bartoletti M; Pascale R; Cricca M; Rinaldi M; Maccaro A; Bussini L; Fornaro G; Tonetti T; Pizzilli G; Francalanci E; Giuntoli L; Rubin A; Moroni A; Ambretti S; Trapani F; Vatamanu O; Ranieri VM; Castelli A; Baiocchi M; Lewis R; Giannella M; Viale P;
    Clin Infect Dis; 2021 Dec; 73(11):e3606-e3614. PubMed ID: 32719848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.
    Gautier-Veyret E; Fonrose X; Tonini J; Thiebaut-Bertrand A; Bartoli M; Quesada JL; Bulabois CE; Cahn JY; Stanke-Labesque F
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2305-14. PubMed ID: 25645831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [COVID-19-associated pulmonary aspergillosis in critically ill patients: experience of a Chilean public hospital].
    Araya-Rojas F; Lasso-Barreto M
    Rev Chilena Infectol; 2021 Dec; 38(6):754-760. PubMed ID: 35506848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients.
    Kooistra EJ; van Berkel M; van Kempen NF; van Latum CRM; Bruse N; Frenzel T; van den Berg MJW; Schouten JA; Kox M; Pickkers P
    Crit Care; 2021 Aug; 25(1):281. PubMed ID: 34353339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive correlation between voriconazole trough concentrations and C-reactive protein levels in patients with chronic pulmonary aspergillosis: A retrospective cohort study.
    Miyakawa-Tanaka K; Suzuki J; Hirasawa Y; Nakamura S; Takeda K; Narumoto O; Matsui H
    J Infect Chemother; 2023 Jul; 29(7):683-687. PubMed ID: 36965708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.